Incyte Corporation

• INCY Stock Price 24h change: +0.92%. From 105.24 USD to 106.21 USD.
• From a technical perspective, INCY maintains a "bullish consolidation" stance; price stays above major moving averages (50-day at $102.22, 200-day at $89.37), with neutral RSI (48.16) and MACD signaling short-term caution.
• TD Cowen raised INCY price target to $128 on January 13, maintaining a "Buy" rating due to strong performance of Jakafi and Opzelura.
• INCY's Phase III Monjuvi study met key goals in first-line lymphoma treatment, supporting long-term growth prospects beyond its core JAK inhibitor franchise.
• Institutional activity shows Campbell & CO Investment Adviser LLC recently acquired 29,222 shares, valued at approximately $2.48 million.
• The 2026 J.P. Morgan Healthcare Conference concluded with an optimistic outlook for the biotech sector, highlighting a shift toward strategic partnerships and a reopening IPO window.
• The FDA announced seeking label changes for GLP-1 and flu shots, while new administrative proposals regarding "Most Favored Nation" pricing for drugs introduced fresh regulatory uncertainty to the sector.

• INCY Stock Price 24h change: -0.67%. From 105.95 USD to 105.24 USD.• From a technical perspective, the stock is showing a "bullish consolidation" near its 52-week highs. While the short-term 20-day SMA remains above the 200-day SMA, a recent minor pullback suggests the market is digesting the 18% gain over the last three months. Support is established around $95.47, with immediate resistance at $112.29.• TD Cowen significantly raised Incyte's price target to $128 from $101 on January 14, citing optimism over the CALR antibody program and recent positive Phase 3 trial data for its lymphoma therapy.• Incyte reported positive top-line results from the Phase 3 frontMIND trial for Monjuvi (tafasitamab) in first-line DLBCL, with plans to submit a supplemental Biologics License Application (sBLA) to the FDA in early 2026.• Goldman Sachs updated its price target for Incyte to $90 from $80 on January 7, maintaining a Neutral rating while acknowledging the company's strong sector performance in 2025 and pipeline potential.• Biopharmaceutical venture investments surged to a three-year high in late 2025, signaling a more aggressive "risk-on" mindset for the healthcare sector entering 2026.• The 2026 J.P. Morgan Healthcare Conference highlighted a "renewed IPO window" and a shift toward innovative, low-risk asset partnerships rather than mega-mergers as patent cliffs loom for major pharma players.